本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 华仁药业股份有限公司 2021 年第三季度报告 证券代码：300110 证券简称：华仁药业 公告编号：2021-063 华仁药业股份有限公司 2021 年第三季度报告 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 429,572,765.53 | 0.75% | 1,132,353,973.74 | 16.63% | | ...

Financial Performance - Huaren Pharmaceutical reported a revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 15%[14]. - The company achieved operating revenue of CNY 702.78 million, representing a year-on-year increase of 19.84%[20]. - Net profit attributable to shareholders reached CNY 73.51 million, a significant increase of 109.34% compared to the same period last year[20]. - Basic earnings per share increased to CNY 0.0622, up 109.43% from the previous year[20]. - The total revenue for the first half of 2021 reached CNY 1,000,000,000, with a year-on-year growth of 35.72%[75]. - The company reported a significant increase in accounts receivable, which may affect asset efficiency, but the new business clients have good credit ratings[95]. - The company reported a total profit of ¥13,716,670.69, compared to ¥6,405,621.02 in the previous year, indicating an increase of about 114.5%[177]. Research and Development - The company plans to invest RMB 100 million in R&D for new drug development in the upcoming year[14]. - Research and development expenses amounted to CNY 34.41 million, reflecting a growth of 29.36% compared to the previous year[29]. - The company is focusing on developing new products in nephrology, respiratory, and narcotic fields, with 21 drug R&D projects and 12 medical device projects ongoing[29]. - The company has obtained drug approval numbers for 21 specifications of peritoneal dialysis solutions, including lactate and low-calcium lactate solutions, marking a strategic product line expansion[43]. - R&D expenses increased to ¥18,534,384.35 from ¥11,842,785.52, representing a growth of approximately 56.8% year-over-year[177]. Market Expansion - Huaren Pharmaceutical is expanding its market presence by entering two new provinces, aiming for a 5% market share in these regions by the end of 2022[14]. - The company has successfully entered over 1,600 hospitals across more than 30 provinces and cities in China[27]. - The company expanded its pharmaceutical commercial business, with international trade efforts resulting in exports of pharmaceutical packaging products to Germany, France, South Korea, and Algeria[33]. - The company is actively responding to national and local procurement policies, accelerating product listings and expanding market access[32]. - The company aims to enhance its comprehensive strength through mergers and acquisitions, focusing on integrating resources and optimizing financial management[38]. Acquisitions and Investments - The company completed the acquisition of a local pharmaceutical firm, which is projected to contribute an additional RMB 50 million in revenue annually[14]. - The company expanded its business by acquiring 100% equity of two pharmaceutical companies, enhancing its product range and market presence[27]. - The acquisition of Xi'an Hengjuxing and Anhui Hengxing Pharmaceutical was completed, enhancing the company's product variety and R&D pipeline, with 17 approved drug varieties and several in clinical research[36]. - The company completed the acquisition of 100% equity in Hengju Star Pharmaceutical Co., Ltd. and Anhui Hengxing Pharmaceutical Co., Ltd. as of July 23, 2021[135]. - The company plans to acquire 100% equity of Anhui Hengxing Pharmaceutical Co., Ltd. for a transaction price based on an average net profit of CNY 80 million over three years[135]. Operational Efficiency - The company optimized its organizational structure to improve operational efficiency and reduce costs, implementing a product manager responsibility system for the entire product lifecycle[35]. - The production model is based on sales-driven production, adhering to GMP standards across all manufacturing processes to ensure product safety and quality[49]. - The company’s non-PVC soft bag infusion products utilize a third-generation fully sealed packaging method, effectively preventing contamination[41]. - The company has established a leading advantage in the non-PVC soft bag infusion field, with a strong R&D system and quality control measures in place[53]. Financial Position - The total assets of the company increased by 34.31% to CNY 4.59 billion compared to the end of the previous year[20]. - The company's total liabilities were CNY 2,200,123,589.28, up from CNY 1,086,029,955.90, which is an increase of approximately 102%[166]. - The company's equity attributable to shareholders increased to CNY 2,314,442,165.48 from CNY 2,258,666,863.54, showing a growth of about 2.5%[166]. - The company’s cash and cash equivalents increased significantly to CNY 424,990,609.90 from CNY 228,670,521.39, reflecting a growth of approximately 86%[163]. Social Responsibility - In the first half of 2021, the company donated 1 million N95 medical masks to support workers during the pandemic[110]. - The company donated 500,000 yuan to Henan Provincial People's Hospital for disaster relief during the floods in July 2021[110]. - The company has actively participated in social responsibility initiatives, receiving awards for contributions to pandemic relief efforts[110]. Risk Management - The company identified potential risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[6]. - The company faces industry policy risks due to the impact of national policies on the pharmaceutical sector, which may lead to increased market competition and price reductions[93]. - Rising costs due to stricter production standards and environmental regulations are challenging the company's cost control efforts[95].

华仁药业股份有限公司 2021 年第一季度报告全文 华仁药业股份有限公司 2021 年第一季度报告全文 华仁药业股份有限公司 2021 年第一季度报告 2022 年 03 月 1 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨效东、主管会计工作负责人韩莉萍及会计机构负责人(会计主 管人员)孟祥园声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 343,348,482.94 | 240,479,398.95 | 42.78% | | 归属于上市公司股东的净利润（元） | 24,826,733.26 | 5,86 ...

华仁药业股份有限公司 2021 年第三季度报告 证券代码：300110 证券简称：华仁药业 公告编号：2021-063 华仁药业股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗 漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 1,571,642,506.60 | 268.62% | 4,097,106,791.45 | 304.53 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[14]. - Net profit attributable to shareholders reached RMB 200 million, up 10% compared to the same period last year[14]. - The management has set a revenue target of RMB 2.5 billion for the full year 2021, indicating a growth forecast of 12%[14]. - The company achieved operating revenue of CNY 2.525 billion, a 330.63% increase compared to the same period last year[20]. - Net profit attributable to shareholders reached CNY 73.51 million, up 109.34% year-on-year[20]. - The company reported a net cash flow from operating activities of -CNY 575.08 million, a decrease of 603.00% compared to the previous year[20]. - Basic earnings per share increased to CNY 0.0622, a growth of 109.43% from the previous year[20]. - The company reported a significant increase in short-term loans to ¥1,361,719,885.94, up from ¥536,651,711, reflecting a 29.68% share of total liabilities[78]. - The company's total assets as of the end of the reporting period amounted to CNY 3,881,023,813.16, compared to CNY 3,148,760,585.00 at the end of the previous year, marking a growth of about 23%[172]. Market Expansion and Product Development - The company plans to expand its market presence by increasing production capacity by 20% in the next year[14]. - The company has launched two new product lines in the therapeutic infusion segment, expected to contribute an additional RMB 100 million in revenue by year-end[14]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[14]. - The company expanded its business scope by acquiring 100% equity of two pharmaceutical companies, enhancing its product offerings[27]. - The company is focusing on developing new products in nephrology, respiratory, and anesthetic fields, with 21 drug R&D projects underway[29]. - The company launched new health products, including glucose rehydration liquid and solid beverages, and signed over 20 distributors for its beverage business in the first half of 2021[34]. - The company has obtained drug approval numbers for 21 specifications of peritoneal dialysis solutions, including lactate and low-calcium lactate solutions, marking a significant strategic product following large-volume infusion solutions[43]. - The company is focusing on expanding its market presence and enhancing its product offerings, which may lead to increased revenue in the future[187]. Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation[14]. - Research and development investment amounted to CNY 34.41 million, representing a 29.36% increase year-on-year[29]. - Research and development expenses for the first half of 2021 were CNY 34,406,701.64, compared to CNY 26,598,514.90 in the previous year, reflecting a growth of approximately 29%[174]. - The company aims to enhance its R&D investment and accelerate the approval and launch of new products to improve profitability and sustainability[95]. Acquisitions and Partnerships - The acquisition of Xi'an Hengjuxing and Anhui Hengxing Pharmaceutical was completed, adding 17 approved drug varieties and enhancing the company's product pipeline in respiratory and controlled drugs[36]. - The company acquired 100% equity of Xi'an Hengjuxing Pharmaceutical Co., Ltd. and Anhui Hengxing Pharmaceutical Co., Ltd. to enhance its product variety and profitability[95]. - The company has completed the acquisition of 100% equity in Hengju Star Pharmaceutical Co., Ltd. and Anhui Hengxing Pharmaceutical Co., Ltd., with the transaction valued at CNY 800 million[137]. - The company’s strategic focus is on expanding its product line and enhancing core competitiveness through acquisitions and partnerships[137]. Risk Management - Risk factors identified include regulatory changes and market competition, with strategies in place to mitigate these risks[6]. - The company faces risks from industry policy changes, which could affect market competition and pricing[95]. - Rising costs due to stricter regulations and supply chain issues are challenging the company's cost control efforts[97]. Corporate Governance and Shareholder Relations - The annual shareholders meeting had a participation rate of 45.32% on April 9, 2021[101]. - The first extraordinary shareholders meeting in 2021 had a participation rate of 36.81% on August 9, 2021[101]. - The company has appointed several new executives, including the CEO and several vice presidents, as of July 23, 2021[102]. - The company distributed cash dividends of 17.73 million yuan to shareholders during the reporting period[112]. - The company has actively participated in social responsibility initiatives, receiving multiple awards for its contributions[114]. Environmental and Social Responsibility - The company reported that it is a key pollutant discharge unit and complies with environmental discharge standards[108]. - The total COD discharge was 1345.5 kg, with a concentration of 27 mg/L, which is within the standard limits[108]. - The company has established a response plan for sudden environmental incidents and conducts regular monitoring of emissions[110]. - The company emphasizes employee rights protection and maintains a harmonious labor relationship[111].

华仁药业股份有限公司 2021 年第一季度报告全文 华仁药业股份有限公司 2021 年第一季度报告 2021 年 04 月 1 华仁药业股份有限公司 2021 年第一季度报告全文 第一节 重要提示 公司负责人杨效东、主管会计工作负责人韩莉萍及会计机构负责人(会计主 管人员)孟祥园声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2021 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业收入（元） | 1,127,868,965.74 | 240,479,398.95 | 369.01% | | 归属于上市公司股东的净利润（元） | 24,826,733.26 | 5,865,601.69 | 323.26% | | 归属于上市公司股东的扣除非经常性 损益的净利润（元） | 21,402,614.74 | 1,922,627.87 | 1,013.20% | | ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2020, representing a year-on-year increase of 15%[14] - The net profit attributable to shareholders was RMB 150 million, an increase of 10% compared to the previous year[14] - The company's operating revenue for 2020 was ¥1,616,318,827.74, representing a 10.56% increase compared to ¥1,461,940,624.48 in 2019[19] - The net profit attributable to shareholders in 2020 was ¥94,623,997.60, a significant increase of 124.94% from ¥42,066,213.53 in 2019[19] - The total profit reached 111.64 million yuan, up 65.61% compared to the previous year[49] - The company achieved a revenue growth of 18% for the next fiscal year, driven by new product launches and market expansion efforts[14] - The sales net profit margin for 2020 was 6%[49] - The company reported a significant increase in revenue from Qingdao Huaren Pharmaceutical Co., Ltd., with total revenue of 241,844,230 CNY and a net profit of 30,211,869 CNY[96] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of RMB 0.15 per 10 shares, totaling approximately RMB 17.8 million[6] - The company distributed cash dividends of 0.15 RMB per share, totaling 17,733,194.73 RMB, representing 18.74% of the net profit for 2020[119] - The profit distribution plan for 2020 was approved, with no stock dividends or capital reserve transfers, indicating a focus on cash returns to shareholders[119] - The company has implemented a cash dividend policy to ensure shareholder returns while maintaining a stable financial policy[159] Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[14] - The company is actively expanding its medical packaging and cardboard box product lines to enhance its pharmaceutical health strategy[30] - The company is positioned to benefit from the ongoing reforms in medical insurance and the promotion of "Internet+" healthcare services, which are expected to enhance service delivery and accessibility[41] - The company aims to enhance its product capabilities and expand into the medical services sector as part of its strategic development plan[102] Acquisitions and Investments - Strategic acquisitions are planned, with a budget of RMB 300 million to enhance the company's product portfolio and distribution channels[14] - The company completed the acquisition of 100% equity in Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pu Bei County Xinke Pharmaceutical Packaging Co., Ltd. in 2020[33] - The acquisition of Guangxi Yuyuan and Pubei Xinke was completed in November 2020, enhancing the company's product range and market coverage[171] - The company has undergone several acquisitions and restructurings, including the acquisition of 100% of the equity of Pubei Xinke Pharmaceutical Packaging Co., Ltd.[98] Research and Development - The company has allocated RMB 50 million for research and development in new technologies for drug delivery systems[14] - The company launched 46 R&D projects in 2020, including 18 pharmaceutical projects and 14 medical device projects[51] - The company obtained 37 new patents during the reporting period, including 8 invention patents, bringing the total to 401 patents by the end of the period[53] - The company has developed a mixed sugar electrolyte injection that meets postoperative patient needs, which has received a registration certificate[77] Risk Management - Risk factors identified include regulatory changes and market competition, with strategies in place to mitigate these risks[6] - The company is facing risks from industry policies, market competition, accounts receivable, and rising costs, which could impact its profitability and operational efficiency[106][108] Social Responsibility and Community Engagement - The company donated CNY 1 million to support frontline medical staff in the fight against the pandemic[157] - The company provided 85 tons of medical supplies urgently needed in Wuhan during the pandemic[157] - The company has established a fund totaling 25360.16 yuan to support employees in need, reflecting its commitment to employee welfare[159] - The company has committed to environmental protection by promoting waste classification and resource utilization in its production processes[160] Operational Efficiency and Management - The company has established a comprehensive after-sales service system to enhance customer satisfaction and protect stakeholder rights[160] - The company has a robust supply chain integration and cost control system, which enhances its competitive edge in the market[112] - The company is committed to maintaining a robust management team to navigate market challenges and opportunities[199] Financial Position and Assets - The company's total assets at the end of 2020 were ¥3,415,544,750.98, a 26.02% increase from ¥2,710,265,463.16 at the end of 2019[19] - The company reported a significant increase in accounts receivable due to the rapid growth of its pharmaceutical business, indicating strong sales performance[85] - The company has recorded a total asset value of 414,753,490 CNY, showcasing its growth potential[96] Governance and Compliance - The company guarantees the independence of its financial accounting department and financial decision-making processes[122] - The company has not engaged in any major related party transactions during the reporting period[139] - The company has implemented the new revenue recognition standards starting from January 1, 2020, as mandated by the Ministry of Finance[131]

华仁药业股份有限公司 2020 年第三季度报告全文 华仁药业股份有限公司 2020 年第三季度报告 2020 年 10 月 1 华仁药业股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨效东、主管会计工作负责人杨效东及会计机构负责人(会计主 管人员)孟祥园声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 2,874,738,843.55 | | 2,710,265,463.16 | 6.07% | | 归属于上市公司股东的净资产 | 2,218,1 ...

华仁药业股份有限公司 2020 年半年度报告全文 华仁药业股份有限公司 2020 年半年度报告 2020-052 2020 年 08 月 1 华仁药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人杨效东、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)孟祥园声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 1、行业政策风险 医药行业是受国家政策影响较大的行业之一，产业政策以及国家、地方性 法律法规的变化，将直接影响医药行业的景气程度。同时，医药行业关系国计 民生，从中长期看，伴随着国家经济的稳定增长、医疗保险体系的逐渐完善、 人口老龄化程度的逐年提高，医药行业有望保持持续增长。国家医疗卫生体制 改革加速推进，医保控费、集采降价等新政策密集实施，给整个医药行业带来 较大的变革，市场竞争也将进一步加剧，药品价格仍然存在下降空间，公司也 将面临着行业政策变革带来的诸多风 ...

华仁药业股份有限公司 2020 年第一季度报告全文 华仁药业股份有限公司 2020 年第一季度报告 2020 年 04 月 1 华仁药业股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人杨效东、主管会计工作负责人王文萍及会计机构负责人(会计主 管人员)李明声明：保证季度报告中财务报表的真实、准确、完整。 2 华仁药业股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增 | | --- | --- | --- | --- | | | | | 减 | | 营业总收入（元） | 240,479,398.95 | 332,837,828.44 | -27.75% | | 归属于上市公司股东的净利润（元） | 5,865,601.69 | 4,90 ...